Stock Market Information
Important financial data
| Particulars | 31.12.2024 | 31.12.2023 | |||
| in thousands of PLN | in thousands of EUR | in thousands of PLN | in thousands of EUR | ||
| 1. | Net revenues from product sales | 0,00 | 0,00 | 0,00 | 0,00 |
| 2. | Operating profit (loss) | -15 033,84 | -3 492,83 | -14 015,08 | -3 094,93 |
| 3. | Gross profit (loss) | -14 867,41 | -3 454,16 | -13 692,82 | -3 023,76 |
| 4. | Net profit (loss) | -14 897,94 | -3 461,26 | -13 687,55 | -3 022,60 |
| 5. | Net cash flow from operating activities | -17 567,38 | -4 081,45 | -14 747,69 | -3 256,71 |
| 6. | Net cash flow from investing activities | -84,24 | -19,57 | -458,35 | -101,22 |
| 7. | Net cash flow from financing activities | 41 974,18 | 9 751,91 | 20 396,28 | 4 504,08 |
| 8. | Total net cash flow | 24 322,56 | 5 650,89 | 5 190,24 | 1 146,15 |
| 9. | Net earnings (loss) per ordinary share (in PLN/EUR) | -3,28 | -0,76 | -3,49 | -0,77 |
| 10. | Diluted net earnings (loss) per ordinary share (in PLN/EUR) | -3,28 | -0,76 | -3,49 | -0,77 |
| Particulars | 31.12.2024 | 31.12.2023 | |||
| in thousands of PLN | in thousands of EUR | in thousands of PLN | in thousands of EUR | ||
| 1. | Total assets | 41 854,21 | 9 795,04 | 12 735,30 | 1 2 929,00 |
| – including cash | 33 632,84 | 7 871,01 | 9 310,28 | 2 141,28 | |
| 2. | Liabilities and provisions for liabilities | 3 436,11 | 804,14 | 2 268,58 | 521,75 |
| 3. | Long-term liabilities | 149,55 | 35,00 | 76,33 | 17,56 |
| 4. | Short-term liabilities | 2 910,25 | 681,08 | 1 888,80 | 434,41 |
| 5. | Equity | 38 418,10 | 8 990,90 | 10 466,72 | 1 2 407,25 |
| 6. | Share capital | 492,45 | 115,25 | 412,95 | 94,97 |
| 7. | Number of shares (pcs.) | 4 924 468,00 | 4 129 468,00 | ||
| 8. | Weighted average number of shares (pcs.) | 4 536 770,00 | 3 919 118,00 | ||
| 9. | Book value per share (PLN/EUR) | 7,80 | 1,83 | 2,53 | 0,58 |
| 10. | Diluted book value per share (PLN/EUR) | 7,80 | 1,83 | 2,53 | 0,58 |
Financial statements
Bioceltix S.A. Financial Statements for the period 01/01/2024-31/12/2024
Report on the activities of Bioceltix S.A. for the reporting period ended December 31, 2024.
Bioceltix S.A. Annual Report for 2024
Auditor's opinion on the financial statements of Bioceltix S.A. for the period from 1 January 2024 to 31 December 2024.
Sprawozdanie Finansowe Bioceltix S.A. za okres 01.01.2023-31.12.2023
Sprawozdanie z działalności Bioceltix S.A. za okres sprawozdawczy zakończony 31.12.2023 r.
Raport okresowy roczny Bioceltix S.A. za rok 2023
Opinia biegłego rewidenta z badania Sprawozdania Finansowego Bioceltix S.A. za okres 01.01.2023-31.12.2023 r.
Sprawozdanie Finansowe Bioceltix S.A. za okres 01.01.2022-31.12.2022
Sprawozdanie z działalności Bioceltix S.A. za okres sprawozdawczy zakończony 31.12.2022 r.
Zmienione sprawozdanie niezależnego biegłego rewidenta z badania rocznego sprawozdania finansowego z dnia 5 maja 2022 r.
Stanowisko Zarządu wraz z opinią Rady Nadzorczej w sprawie zastrzeżenia wyrażonego w Opinii biegłego rewidenta z badania Sprawozdania Finansowego Bioceltix S.A. za okres 01.01.2022-31.12.2022
Information
Financial forecasts
The Company does not publish financial forecasts.
Recommendations and analyses on the company
Dividend policy
The Company has not adopted a dividend policy. Future decisions regarding dividend payments or the allocation of profits—either in whole or in part—to reserve capital will be made by the General Meeting of Shareholders, subject to applicable legal regulations.